Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vildagliptin + metformin
- Development stage
- Phase 3
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vildagliptin + metformin is a fixed-dose oral combination therapy for type 2 diabetes mellitus. It combines two antihyperglycemic agents with complementary mechanisms of action. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones (GLP-1 and GIP), thereby enhancing insulin secretion and reducing glucagon release in a glucose-dependent manner. Metformin is a biguanide that decreases hepatic glucose production and improves peripheral insulin sensitivity by activating AMPK. The combination provides improved glycemic control compared to either agent alone and is indicated for adults with type 2 diabetes inadequately controlled on monotherapy or as part of triple therapy regimens[1][3][5][6]. The product was developed by Novartis.
- Brand names
- EucreasGalvumetZomaristGalvus Met
- Other names
- vildagliptin/metforminvildagliptin + metformin hydrochloride
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on vildagliptin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vildagliptin + metformin.